Johnson & Johnson (JNJ) Stock Hit an All-Time High — And Analysts Think There’s More to Come

TLDR

• JNJ hit an all-time high of $264.98, with the stock now trading around $268.69, up 3.70% on the day
• The stock has delivered a 71% total return over the past year
• Guggenheim raised its price target to $270 and maintained a Buy rating, expecting Q2 revenue of $25.48 billion
• J&J raised its quarterly dividend to $1.34 per share, up from $1.30, marking 55 consecutive years of dividend increases
• Institutional buying has been heavy, with Vanguard, State Street, and Norges Bank all adding or establishing positions

Johnson & Johnson hit a fresh all-time high on Tuesday, touching $264.98 before pushing further to $268.69 — a gain of 3.70% on the day. The move puts JNJ’s market cap at roughly $646.8 billion.

Johnson & Johnson, JNJ

The stock is up 71% over the past twelve months, with a twelve-month low of $154.21 now firmly in the rearview mirror.

At current levels, JNJ trades at a P/E ratio of 31.02 and a P/E/G of 2.58. The stock’s fifty-day moving average sits at $233.72, and the two-hundred-day at $231.37 — both well below where the stock is now.

Trading volume on Tuesday came in at 1.79 million, well below the average of 8.41 million. That kind of low-volume grind higher is sometimes a sign of steady accumulation rather than a frenzied spike.

Analyst Targets Getting Tested

Guggenheim recently raised its price target to $270, maintaining a Buy rating. The firm expects J&J to post Q2 revenue of $25.48 billion and EPS of $2.87.

Leerink upgraded the stock from Market Perform to Outperform back in May, setting a $265 price target — a level JNJ has now cleared. Wells Fargo rates it Overweight with a $263 target.

The consensus across 27 analysts is a “Moderate Buy” with a mean price target of $257.13. With the stock trading above that level, the bulls are running ahead of the Street.

Bank of America and Barclays both carry neutral/equal weight ratings, with targets of $254 and $255 respectively.

Dividend and Earnings

J&J’s most recent quarterly earnings, reported April 14, showed EPS of $2.70, beating the consensus of $2.68. Revenue came in at $24.06 billion against estimates of $23.60 billion — a 9.9% year-over-year increase.

The company also raised its quarterly dividend to $1.34 from $1.30, paid out on June 9. That puts the annualized dividend at $5.36, with a current yield of around 2.0%.

J&J has now raised its dividend for 55 consecutive years, keeping it firmly in Dividend King territory. The payout ratio sits at 61.97%.

FY2026 EPS guidance is set at $11.45–$11.65, with analysts forecasting $11.57.

Institutional Buying and Insider Activity

Institutional investors hold 69.55% of JNJ. Vanguard added 3.73 million in Q4, bringing its total to 240.35 million. State Street added 1.66 million to hold 133.87 million. Norges Bank established a new position worth roughly $6.92 billion.

Moran Wealth Management increased its stake by 15.4% in Q1, buying 12,160 additional units to hold 90,903, valued at $22.2 million.

On the insider side, EVP Kathryn Wengel sold 10,000 units at $241.15 on June 11, reducing her position by 8.05%. She still holds 114,288 units valued at roughly $27.6 million.

J&J also announced a $1 billion-plus investment in its Jacksonville, Florida operations to expand manufacturing for its Vision business, including increased capacity for ACUVUE contact lenses.

New data on IMAAVY (nipocalimab-aahu) for myasthenia gravis was presented across 12 abstracts at the European Academy of Neurology 2026 Congress.

The post Johnson & Johnson (JNJ) Stock Hit an All-Time High — And Analysts Think There’s More to Come appeared first on CoinCentral.